BeiGene (BGNE) has a profit margin of 13.86%, below the Healthcare sector average of 19.13%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
BeiGene (BGNE) currently reports a profit margin of 13.86% as of September 2026. That compares with 1.38% in the prior-year period — up 905.3% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore BeiGene's profit margin history and peer comparisons.
BeiGene's profit margin increased from 1.38% to 13.86% — a 905.3% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
BeiGene's profit margin of 13.86% is lower than the Healthcare sector average of 19.13%. That is roughly 27.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but BeiGene's current 13.86% should be judged against Healthcare norms (sector average: 19.13%) and against BGNE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of 13.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for BeiGene, and consider following BGNE for alerts when major investors trade the stock.